Prognostic significance of phospho-histone H3 in prostate carcinoma

World Journal of Urology

Volumn 32, Issue 3, 2014, Pages 703-707

  Nowak, Michael ^a   Svensson, Maria A ^b,c   Carlsson, Jessica ^b,c   Vogel, Wenzel ^a   Kebschull, Moritz ^d   Wernert, Nicolas ^a   Kristiansen, Glen ^a   Andrén, Ove ^b,c   Braun, Martin ^a   Perner, Sven ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c ÖREBRO UNIVERSITY   (Sweden)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

Mitosis; Phospho histone H3; Prognostic marker; Prostate cancer

Indexed keywords

HISTONE; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGED; BIOSYNTHESIS; CANCER GRADING; CELL PROLIFERATION; CONTROLLED STUDY; EPIDEMIOLOGY; GERMANY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CELL PROLIFERATION; GERMANY; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84901504127     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-013-1135-y     Document Type: Article

References (22)

1. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, Mihatsch MJ (1996) Ki-67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 178(4): 437-441.
2. Borre M, Bentzen SM, Nerstrom B, Overgaard J (1998) Tumor cell proliferation and survival in patients with prostate cancer followed expectantly. J Urol 159(5): 1609-1614.
3. Cheng L, Pisansky TM, Sebo TJ, Leibovich BC, Ramnani DM, Weaver AL, Scherer BG, Blute ML, Zincke H, Bostwick DG (1999) Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression. Clin Cancer Res 5(10): 2820-2823.
4. Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M 3rd, Shipley WU, Hanks GE, Sandler HM (2004) Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: radiation therapy oncology group trial 92-02. J Clin Oncol 22(11): 2133-2140.
5. Gallee MP, van Steenbrugge GJ, ten Kate FJ, Schroeder FH, van der Kwast TH (1987) Determination of the proliferative fraction of a transplantable, hormone-dependent, human prostatic carcinoma (PC-82) by monoclonal antibody Ki-67: potential application for hormone therapy monitoring. J Natl Cancer Inst 79(6): 1333-1340.
6. Oomens EH, van Steenbrugge GJ, van der Kwast TH, Schroder FH (1991) Application of the monoclonal antibody Ki-67 on prostate biopsies to assess the fraction of human prostatic carcinoma. J Urol 145(1): 81-85.
7. McLoughlin J, Foster CS, Price P, Williams G, Abel PD (1993) Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma. Br J Urol 72(1): 92-97.
8. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133(4): 1710-1715.
9. Shibata K, Inagaki M, Ajiro K (1990) Mitosis-specific histone H3 phosphorylation in vitro in nucleosome structures. Eur J Biochem 192(1): 87-93.
10. Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH, Soiland H, Baak JP (2007) Phospho-histone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol 20(12): 1307-1315.
11. Nasr MR, El-Zammar O (2008) Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol 30(2): 117-122.
12. Aune G, Stunes AK, Tingulstad S, Salvesen O, Syversen U, Torp SH (2011) The proliferation markers Ki-67/MIB-1, phospho-histone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. Int J Clin Exp Pathol 4(5): 444-453.
13. Brunner A, Riss P, Heinze G, Brustmann H (2012) pHH3 and survivin are co-expressed in high-risk endometrial cancer and are prognostic relevant. Br J Cancer 107(1): 84-90.
14. Hightower E, Cabanillas ME, Fuller GN, McCutcheon IE, Hess KR, Shah K, Waguespack SG, Corley LJ, Devin JK (2012) Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas. Pituitary 15(4): 556-561.
15. Ladstein RG, Bachmann IM, Straume O, Akslen LA (2012) Prognostic importance of the mitotic marker phospho-histone H3 in cutaneous nodular melanoma. J Invest Dermatol 132(4): 1247-1252.
16. Sun A, Zhou W, Lunceford J, Strack P, Dauffenbach LM, Kerfoot CA (2012) Level of phospho-histone H3 among various types of human cancers. BMJ Open 2(5).
17. Braun M, Stomper J, Kirsten R, Shaikhibrahim Z, Vogel W, Bohm D, Wernert N, Kristiansen G, Perner S (2013) Landscape of chromosome number changes in prostate cancer progression. World J Urol.
18. Scheble VJ, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T, Stiedl AC, Petersen K, Reischl M, Kuefer R, Schilling D, Fend F, Kristiansen G, Meyerson M, Rubin MA, Bubendorf L, Perner S (2010) ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 23(8): 1061-1067.
19. Braun M, Kirsten R, Rupp NJ, Moch H, Fend F, Wernert N, Kristiansen G, Perner S (2013) Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system. Histol Histopathol.
20. Baatz M, Zimmermann J, Blackmore CG (2009) Automated analysis and detailed quantification of biomedical images using definiens cognition network technology. Comb Chem High Throughput Screen 12(9): 908-916.
21. Bubendorf L, Tapia C, Gasser TC, Casella R, Grunder B, Moch H, Mihatsch MJ, Sauter G (1998) Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 29(9): 949-954.
22. Ladstein RG, Bachmann IM, Straume O, Akslen LA (2010) Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer 10: 140.